WHO advice – Ramadasivir should not be used for hospitalized corona patients

Rem Shadi Remedisvir of Gilead, however, was ill, but not hospitalized Kovid-19 patients, a World Health Organization panel said Friday. The committee said there was no evidence to suggest that the drug could improve the patient’s condition or reduce the need for ventilation. The guidelines said the panel found a lack of evidence indicating that Remedisvir reduced mortality or decreased the need for ventilation. These guidelines .The biggest drawback to the industry. The drug has received worldwide attention and has shown some promise as an effective treatment for Kovid-19 in the summer following initial testing.

At the end of October, Gilead slashed its 2020 revenue forecast, citing lower demand and difficulties than Remedisvir’s sales forecast. Antiviral drug is one of two drugs authorized to treat Kovid-19 patients worldwide, but last month a large WHO-led trial known as the Solidarity Trial showed a 28-day mortality or length that had little or no effect.

This drug is one of the drugs used by US President Donald Trump to treat a coronavirus infection, and previous studies have shown that the drug has reduced recovery time. It has been authorized to be used as a covid-19 treatment in more than 50 countries. Gilead challenged the results of the Solidarity Inquiry. The WHO’s Guidance Development Group (GDG) committee said its recommendation was based on a review of evidence from four international randomized trials involving more than 7,000 patients hospitalized with Kovid-19.

Upon reviewing the evidence, it is concluded that Remedisvir has no meaningful effect on patient mortality or other significant outcomes and is expensive and complex to administer. Following recent advice from the WHO, which represents acute care physicians at the world’s top institutions, Kovid-19 patients in critical care wards should not be treated with ish medicine.

Read also – New mask of anti-viral layer neutralizes corona virus: study

The WHO recommendation is part of its “Survival Guidelines” program, which is designed to guide physicians about patients in rapidly growing conditions such as the Covid-19 epidemic. To assist in clinical decision making. Guidelines can be changed when new evidence and information is revealed. The committee said it would support continued enrollment in clinical trials evaluating remediation in COVID-19 patients, which “should provide further evidence to specific groups of patients.”


Disclaimer: The above information is for general informational purposes only. All information on the Site is provided in good faith, however we make no representation or warranty of any kind, express or implied, regarding the accuracy, adequacy, validity, reliability, availability or completeness of any information on the Site.